Daniel Adelman International Celiac Disease Symposium 2026

Daniel Adelman

Dr. Daniel Adelman holds an academic appointment at the University of California, San Francisco as Adjunct Professor of Medicine; is a fellow of the American Academy of Allergy and Immunology, the Clinical Immunology Society, and the American College of Physicians. Dr. Adelman trained in Internal Medicine and was a Clinical and Research post-doctoral fellow at UCLA in the Division of Clinical Immunology and Allergy where he completed a National Institutes of Health/Public Health Service Tumor Immunology Fellowship. Dr. Adelman joined the faculty at University of California, San Francisco, School of Medicine, where he was Director of Clinical Allergy/Immunology in the Division of Allergy and Immunology, and Director of the Outpatient Center for Clinical Research. He holds an AB degree in Biology from University of California, Berkeley and received his M.D. from the University of California, Davis. For over 30 years, Dr. Adelman has been developing novel therapeutics in the Biotechnology Industry in the San Francisco Bay Area. Dr. Adelman was Chief Medical Officer at Aimmune Therapeutics where he was responsible for leading the development of Palforzia®, the first FDA/EMA approved treatment for patients with food allergies. Prior to that he was Senior Vice President of Development and Chief Medical Officer at Alvine Pharmaceuticals Inc., a biotechnology company devoted to the development of a pharmaceutical treatment for celiac disease. Earlier in his career, Dr. Adelman was Senior VP, Development and Chief Medical Officer at Sunesis Pharmaceuticals, served in various roles at Pharmacyclics, including VP, Clinical Operations and Biometrics and was a Clinical Scientist at Genentech where he led the early clinical development of two therapeutic monoclonal antibodies, Xolair® and Avastin®. Dr. Adelman has been involved in all stages of pharmaceutical drug development and is extensively published.